In its third quarter 2024 earnings report, Passage Bio highlighted significant progress in its PBFT02 program, aimed at treating frontotemporal dementia (FTD-GRN). The company shared updates on ...
The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from March 2013 through June 2018, who had used gabapentinoids before the injury ...
SPPPOOOOOOKKKYYYYY!!!WOO NEW MERCH! Roblox Links:White Logo: <a href="https://www.roblox.com/catalog/108328...Black">https://www.roblox.com/catalog/108328...Black</a ...
CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback